Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer

The aim of the present study was to observe the efficacy of neoadjuvant trastuzumab combined with docetaxel and carboplatin (TCH), and docetaxel, epirubicin and cyclophosphamide (TEC) chemotherapy in human epidermal growth factor receptor-2 (HER-2)-overexpressing breast cancer. The total cohort of 6...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology letters 2015-04, Vol.9 (4), p.1922-1926
Hauptverfasser:	CHEN, WEICAI, HE, JINSONG, SONG, SHUFEN, WANG, MIN, WU, HUISHENG, WANG, XIANMING
Format:	Artikel
Sprache:	eng
Schlagworte:	Biopsy Breast cancer Cancer research Cancer therapies Chemotherapy Chinese medicine Drug therapy Edema Family medical history Gene amplification human epidermal growth factor receptor-2 overexpression Medical diagnosis Metastasis Monoclonal antibodies neoadjuvant Oncology Patient outcomes Precision medicine Studies Targeted cancer therapy Trastuzumab Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The aim of the present study was to observe the efficacy of neoadjuvant trastuzumab combined with docetaxel and carboplatin (TCH), and docetaxel, epirubicin and cyclophosphamide (TEC) chemotherapy in human epidermal growth factor receptor-2 (HER-2)-overexpressing breast cancer. The total cohort of 64 cases of HER-2-overexpressing breast cancer patients was divided into two groups according to their treatment preferences: The TCH group, consisting of 39 patients, and the TEC group, consisting of 25 patients. The neoadjuvant chemotherapy was continued for six cycles prior to comparison of the treatment efficacy. The TCG and TEC groups exhibited an overall response rate of 94.9 and 72.0% (37/39 and 18/25 cases; P
ISSN:	1792-1074 1792-1082
DOI:	10.3892/ol.2015.2912